-
Hi Bertrand,
No, i did not pay 3000$.. i think i saw this in genomeweb article.
You may also be interested in the only two surveys i am aware of with publicly available results:
http://seqanswers.com/forums/showthread.php?t=1108
http://seqanswers.com/forums/showthread.php?t=2273
cheers,
s.Leave a comment:
-
Other makes
Yes, I did forget Helicos (and also the Polonator), but these are still very small contributors... Can you tell a little more about the market study you saw (I suppose it is one of these $3,000 studies and is not available)?
Anyway, thanks for your reply, and I'm happy to see that my ballpark estimate seem to be reasonable.
Cheers,
BertrandLeave a comment:
-
Leave a comment:
-
whilst I also don't have access to any official numbers either, your estimate sounds about right -- based on what ive heard.Leave a comment:
-
Instrument statistics, anyone?
The number of machines sold by each major manufacturer is a closely guarded secret - they gave some figures at the beginning, but no longer now (as far as I've been able to see). Does anyone have firm or semi-firm estimates? My own guestimate is around 1,000 systems sold altogether, more than half being Illumina and the rest shared (about equally) between 454 and SOLiD...
Do you agree, disagree?
All replies will be VERY welcome!
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Leave a comment: